These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2905254)

  • 1. Interaction of roxatidine acetate with antacids, food and other drugs.
    Labs RA
    Drugs; 1988; 35 Suppl 3():82-9. PubMed ID: 2905254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic characteristics of roxatidine.
    Bender W; Brockmeier D
    J Clin Gastroenterol; 1989; 11 Suppl 1():S6-19. PubMed ID: 2572622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of roxatidine acetate and cimetidine on hepatic drug clearance assessed by simultaneous administration of three model substrates.
    Tanaka E; Nakamura K
    Br J Clin Pharmacol; 1989 Aug; 28(2):171-4. PubMed ID: 2570603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug interactions between theophylline and H2-antagonists, roxatidine acetate hydrochloride and cimetidine: pharmacokinetic analysis in rats in vivo.
    Nagai N; Furuhata M; Ogata H
    Biol Pharm Bull; 1995 Nov; 18(11):1610-3. PubMed ID: 8593491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of the histamine H2 receptor antagonist roxatidine acetate on stomach and liver alcohol dehydrogenase and serum alcohol level].
    Beil W; Sewing KF
    Z Gastroenterol; 1993 Nov; 31(11):643-5. PubMed ID: 7904786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the animal pharmacology of roxatidine acetate.
    Scholtholt J; Bickel M; Herling AW
    Drugs; 1988; 35 Suppl 3():30-40. PubMed ID: 2905247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical and biologic characteristics of roxatidine acetate.
    Bickel M; Herling AW; Schoelkens B; Scholtholt J
    Scand J Gastroenterol Suppl; 1988; 146():78-88. PubMed ID: 2906471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of roxatidine acetate on 24-hour intragastric acidity. Investigations in healthy volunteers and comparison with ranitidine and placebo.
    Merki HS; Witzel L; Kaufmann D; Kempf M; Neumann J; Scheurle E; Röhmel J; Walt RP
    Drugs; 1988; 35 Suppl 3():69-75. PubMed ID: 2905252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacology of histamine H2-receptor antagonists.
    Sewing KF; Beil W; Hannemann H
    Drugs; 1988; 35 Suppl 3():25-9. PubMed ID: 2905246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of roxatidine in healthy volunteers.
    Collins JD; Pidgen AW
    Drugs; 1988; 35 Suppl 3():41-7. PubMed ID: 2905248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men.
    Lassman HB; Ho I; Puri SK; Sabo R; Scheffler MR
    Drugs; 1988; 35 Suppl 3():53-64. PubMed ID: 2905250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of roxatidine acetate on daytime and night-time peptone-stimulated gastric acid secretion.
    Hagenmüller F
    Drugs; 1988; 35 Suppl 3():65-8. PubMed ID: 2905251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of roxatidine acetate on 24-hour gastric acidity. Early evening versus bedtime administration in healthy subjects.
    Hemery P; Congard P; Galmiche JP; Bonfils S
    Drugs; 1988; 35 Suppl 3():76-81. PubMed ID: 2905253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea.
    Sekiguchi H; Hamada K; Kobayashi F; Taga F; Uchida H
    Arzneimittelforschung; 1993 Feb; 43(2):129-33. PubMed ID: 8096132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic approach in patients with concomitant disease/drug--drug interactions (roxatidine acetate).
    Collins JD
    Scand J Gastroenterol Suppl; 1988; 146():89-99. PubMed ID: 2906472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.
    Murdoch D; McTavish D
    Drugs; 1991 Aug; 42(2):240-60. PubMed ID: 1717223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of roxatidine acetate and ranitidine in the treatment of reflux esophagitis. The Roxatidine Esophagitis Study Group.
    Clin Ther; 1993; 15(2):283-93. PubMed ID: 8100189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoprotective action of roxatidine acetate HCl.
    Shiratsuchi K; Fuse H; Hagiwara M; Mikami T; Miyasaka K; Sakuma H
    Arch Int Pharmacodyn Ther; 1988; 294():295-304. PubMed ID: 2906796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
    Stass H; Böttcher MF; Ochmann K
    Clin Pharmacokinet; 2001; 40 Suppl 1():39-48. PubMed ID: 11352441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.